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ABSTRACT: One of the most daunting challenges of nanomedicine is the finding of appropriate 
targeting agents to deliver suitable payloads precisely to cells affected by malignancies. Even more 
complex is to achieve the ability to ensure the nanosystems enter those cells. Here we use  2 nm 
(metal core) gold nanoparticles to target human hepatocellular carcinoma (HepG2) cells stably 
transfected with the SERPINB3 (SB3) protein. The nanoparticles were coated with a 85:15 mixture 
of thiols featuring, respectively, a phosphoryl choline, to ensure water solubility and 
biocompatibility, and a 28-mer peptide corresponding to the amino acid  sequence 21-47 of the 
hepatitis B virus-PreS1 protein (PreS1(21-47)). Conjugation of the peptide was performed via the 
maleimide-thiol reaction in methanol allowing the use of a limited amount of the targeting 
molecule. This is an efficient  procedure also in the perspective of selecting libraries of new 
targeting agents. The rationale behind the selection of the peptide is that SB3, which is 
undetectable in normal hepatocytes, is over-expressed in hepatocellular carcinoma and in 
hepatoblastoma and has been proposed as a target of the hepatitis B virus (HBV). For the latter 
the key recognition element is the PreS1(21-47) peptide, which is a fragment of one of the 
proteins composing the viral envelope. The ability of the conjugated nanoparticles to bind the 
target protein SB3, expressed in liver cancer cells, was investigated by surface plasmon resonance 
analysis and in vitro via cellular uptake analysis followed by atomic absorption analysis of digested 
samples. The results showed that the PreS1(21-47) peptide is a suitable targeting agent for cells 
overexpressing the SB3 protein. Even more important is the evidence that the gold nanoparticles 
are internalized by the cells. The comparison between the surface plasmon resonance analysis and 
the cellular uptake studies suggests the presentation of the protein on cell surface is critical for 
efficient recognition.  
 
 
INTRODUCTION 
Nanomedicine has developed as a platform to allow, in principle, sophisticated and smart drug 
delivery within the size window of a submicroscopic system that enables delicate and complex 
interactions with cancer cells and their biological milieu. The size scale of the nanosystems (1-100 
nm), closer to proteins and viruses than to molecules, changes the nature of the interactions and, 
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consequently, distribution in the biological environment with respect to traditional drugs.
1
 The 
self-organized nature of the nanoparticles prepared by bottom-up approaches allows the 
exploration of new therapeutic and diagnostic modalities
2,3
 also via the exploitation the 
multivalent and multifunctional properties of the systems.
4
 
Notwithstanding such an amount of advantages, very few nanosystems are currently used 
in the clinical practice.
5,6 
This is because several issues still need to be addressed for the 
development of effective nanotheranostic agents, among which targeting is one of the most 
relevant. First generation nanomedicine agents (including the few liposomal preparations 
currently approved, which represent the large majority of the nanomedicine agents entered in the 
clinical use) were based on the enhanced permeation and retention (EPR) effect. Here, the 
leakiness of the immature tumor vasculature combined with poor lymphatic drainage, causes 
relatively large (10-100 nm) entities to preferentially accumulate in the cancer tissues.
7,8
 However, 
EPR effect is not general. Furthermore, nanoparticles larger than the threshold of the renal filters 
(5 nm) cannot be easily cleared from the organism, leading to long term accumulation.
9
 These 
problems led to the development of second generation nanosystems based on active targeting 
strategies, which include conjugation of nanosystems with antibodies or ligands for receptors 
overexpressed by the target cells.
10
  For this reason the selection of new targeting agents is very 
important and requires a strict collaboration between chemists, biologists, and medical doctors.  
Furthermore, even when targeting has been achieved, internalization of the nanosystem cannot 
be taken for granted.
11
  Several factors affect nanoparticles uptake by cells including charge
12
 and 
the presence of specific peptides (e. g. TAT).
13
 Hence, the synthesis of nanoparticles able not only 
to target specific cells but also characterized by an enhanced uptake by them would represent a 
significant achievement. 
In this paper we show how 2-nm diameter monolayer-protected gold nanoparticles 
conjugated with a 28-mer peptide designed for  the targeting of SERPINB3 expressing cells (the 
PreS1(21-47) fragment) not only bind to the selected target but are internalized into the cells. We 
do not address their ultimate localization within the cells as this is not a major issue when the aim 
is cancer cells targeting and, eventually, their killing. 
SERPINB3 (SB3, also known as Squamous Cell Carcinoma Antigen 1, SCCA1) is a soluble 
serine protease inhibitor of the ovalbumin-serin protease family (ov-serpins). This protein is 
frequently upregulated in several malignancies of epithelial origin in the liver. Indeed, it is 
undetectable in normal hepatocytes, but it is over-expressed in hepatocellular carcinoma (HCC) 
and in hepatoblastoma.
14,15,16,17,18
  Few years ago some of us
19,20,21
 as well as others
22,23
 have 
demonstrated that SB3 is also a target of the hepatitis B virus (HBV), and a key recognition 
element is the PreS1(21-47) peptide, which is a fragment of one of the proteins composing the 
viral envelope. Other target proteins have been suggested for the HBV capsid,
24
 particularly for the 
PreS1 region. Our results confirm that SB3 is one of them and the PreS1(21-47) peptide represents 
not only a new potential targeting agent for hepatic cancer but also for cargo internalization into 
cells. The implications for possible applications in cancer therapy are obvious. 
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RESULTS AND DISCUSSION 
In this study, 2-nm metal core gold nanoparticles (AuNPs), coated with a monolayer of thiols were 
used as candidate nanosystem.
25,26
 The monolayer of organic molecules that protects the 
nanocluster is made by thiols strongly bound to the gold surface. These thiols typically bear at the 
opposite end functional groups that tailor the biological properties of the nanoparticles. 
Preparation of the nanoparticles is much simpler than that of functional polymers or dendrimers, 
since the single functional units can be synthesized separately and then self-assembled on the gold 
core. On the other hand, their non-dynamic nature ensures higher stability with respect to 
liposomes and lipid nanoparticles. For these reasons these nanoparticles represent probably the 
most suitable platform for the preparation of multivalent functional nanosystems for the ease of 
preparation, the stability, and the very low toxicity.
27
 
 Synthesis and characterization of the AuNPs.  We used a two-phase, two-steps synthetic 
procedure to prepare the monolayer-coated nanoparticles.
28
 Briefly, the gold cores are prepared 
in toluene by reduction of HAuCl4 with NaBH4, in the presence of tetrabutylammonium bromide as 
phase transfer agent and dioctylamine as capping agent. The nanoparticles size is controlled by 
the amount of dioctylamine, which acts as a weak surface stabilizer. Subsequent addition of a 
thiol, or of a mixture of thiols, results into the displacement of the amine and the formation of the 
final protecting monolayer. There are several advantages in the use of this method. First, since the 
metal core synthesis and thiol monolayer formation are separated, several samples of 
nanoparticles with the same core size and dispersion and different coatings can be prepared by 
batch splitting. Second, a good control of the monolayer composition can be achieved. Third, the 
use of the weaker stabilizing agent (dioctylamine) ensures a smaller size dispersion. 
 
Figure 1. AuNP characterization: a) Thiols used for nanoparticles passivation, b) TEM picture of 1/2-AuNP (inset: UV-
Vis spectrum in water); c) 
1
H-NMR spectra of 1/2-AuNP (1), 1/2-AuNP after conjugation with MPBS (2), PreS1-AuNPs 
(3); d) FT-IR spectra of the same samples. The blue and pink strips in the spectra highlight the regions showing the 
relevant modifications described in the text as a consequence of the conjugation. 
Page 3 of 14
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
Thiols 1 and 2 were selected as coating elements (Figure 1a). Thiol 1, bearing the 
zwitterionic and biocompatible phosphorylcholine headgroup, was supposed to give the 
nanoparticles “stealth” properties by decreasing proteins absorption.
29,30
 Thiol 2 features a 
terminal primary amino-group easily exploitable for conjugation of the targeting agents. The 1 to 2 
ratio in the nanoparticles was adjusted around 10:1 in order to give them targeting properties 
without affecting multivalency and the ability to escape RES capture. Nanoparticles purification 
was performed by gel-permeation chromatography. Both 1-, and  1/2-coated nanoparticles were 
found to be fully soluble in water and saline solutions for several weeks. Size of the metal cores 
from TEM analysis resulted to be 1.8 ± 0.5 nm and 1.9 ± 0.5 nm for 1-, and  1/2-coated 
nanoparticles, respectively (see Figure 1b for 1/2-AuNP). Such value is confirmed by the UV-Vis 
spectrum of the nanoparticles, that reveals the absence of the plasmonic absorption band at 520 
nm (Figure 1b), typical of gold nanoparticles with a metal core diameter larger than 3 nm. 
Monolayer purity and composition was assessed by 
1
H-NMR (see Supporting Information). NMR 
analysis after iodine decomposition for the 1/2-coated nanoparticles yielded a 1 to 2 ratio of 92:8. 
Average formulas for the two nanoparticles is, accordingly, Au180170 and Au18016327, 
respectively.
31,32 
 
 The CysPreS1(21-47) peptide (CPNFDWDPNNSNAGFAPDLQHDPFFGLP) presents a cysteine 
at the C terminus of the PreS1(21-47) sequence. The presence of the thiol group in the cysteine 
side chain allows the easy conjugation to the nanoparticles via maleimide-thiol addition. In 
principle, one could consider direct conjugation of the peptide to the gold surface. However, this 
would have resulted in its partial burying in the monolayer constituted by zwitterionic thiol 1 and a 
loss of peptide surface suitable for binding to the target. The 1/2-AuNPs were reacted with the 
crosslinker MPBS in DMF/methanol, to introduce the maleimide functional group, and 
subsequently conjugated with the CysPreS1(21-47) peptide in methanol to obtain the PreS1-
AuNPs. Purification was performed by size exclusion chromatography and effective conjugation 
was confirmed by NMR and FT-IR spectroscopy (Figures 1c and 1d). Assuming a quantitative 
conversion of 2 in the peptide conjugate and on the basis of the thiols ratio on the nanoparticles 
reported above there will be, on average, seven peptides per AuNP.  
In the NMR spectra of 1/2–coated nanoparticles small signals at 6.5 and 2.3 ppm appeared 
after MPBS conjugation, arising respectively from the protons of the vinyl group and of the 
methylene adjacent to the carbonyl group of the crosslinker. Upon reaction with the CysPreS1 
derivative, the maleimide signal at 6.5 ppm disappeared to be substituted by a broad signal at 7.1 
ppm, arising from the aromatic side chains of the Phe and Trp residues of PreS1, thus confirming 
the full conversion of the maleimide group into the conjugate. The FT-IR analysis provided a clear-
cut evidence of the presence of the peptide in the purified nanoparticle sample (Figure 1d). 
Unconjugated particles showed a weak absorption at 1680 nm due to the amide group of thiol 2. 
After coupling with MPBS, a new signal at 1720 nm appeared due to the carbonyl groups of the 
maleimide. Finally, after conjugation with the peptide, absorption at 1680 strongly increased due 
to the large number of amide groups present in the peptide. 
 Interaction of the AuNPs with the target protein SERPINB3. The ability of the conjugated 
peptide to interact with the target SB3 protein was first assessed by surface plasmon resonance 
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(SPR) analysis, which allows for the direct measurement of the binding events. The SB3 protein 
was immobilized on a dextrane-coated gold chip via amide coupling (about 2 ng/mm
2
) and 
exposed to increasing concentrations of CysPreS1, 1-AuNPs, and PreS1-AuNPs. Experiments 
performed with the CysPreS1 peptide did not reveal any interaction (see Supporting Information). 
Such an outcome was likely the result of the low molecular weight of the peptide, that reduced 
the amplitude of the instrument response, and of the possible low affinity of the peptide for SB3 
at the concentration interval explored.
20,23
 On the other hand, 1-AuNPs revealed a quite strong 
binding (Figure 2). Association and dissociation profiles were rather complex and could be fitted 
only with a kinetic model which includes two different binding modes of the nanoparticles to SB3 
(see Supporting Information). Fitting results indicated that both binding events were characterized 
by very low dissociation constants (Kd,1 = 1.1×10
-11
 M, Kd,2 = 1.8×10
-11
 M) but featured different 
binding and release rates and interfered with each other. The first binding mode was 
characterized by fast association and dissociation rates (kin = 8.8×10
9
 M
-1
sec
-1
 and kout = 9.5×10
-2
 
sec
-1
) and a low amount of binding sites (8% at low nanoparticles concentrations). The second type 
of binding sites featured slower binding and dissociation (kin = 1×10
8
 M
-1
sec
-1
  and  kout = 2×10
-3
 
sec
-1
). Such sites were predominant (92%) at low nanoparticles concentrations and decreased 
progressively when the amount of AuNPs injected was increased. Apparently saturation of the first 
binding sites by increasing the nanoparticle concentration disfavoured the binding to the second.  
The presence of the PreS1 peptide in PreS1-AuNp led to greater binding (the maximum RU value 
reached is 200 vs 130 for 1-AuNP) but  did not appear to increase the affinity for the protein (Kd,1 = 
1.1×10
-11
 M, Kd,2 = 1.6×10
-11
 M). This is probably due to the fact that the high unspecific affinity of 
the monolayer made by 1 masked the specific binding of PreS1 to SB3 (Figure 2). Control 
experiments performed using non-functionalized chips or chips functionalized with different 
proteins confirmed the specific affinity of SB3 for 1-AuNP (see Supporting Information).  This was 
very disappointing, considering the reported
29
 little affinity of zwitterionic nanoparticles to 
proteins. These data do not allow drawing any conclusion on the advantage of functionalizing the 
nanoparticles with the PreS1 peptide as a targeting agent. We can only state that it does not affect 
it negatively. 
      
 
Figure 2. SPR analysis of the interaction between SB3 and nanoparticles: a) Kinetic assays (Multi Cycle) of 1-AuNP and 
fitting as heterogeneous ligand; b) Kinetic assays (Multi Cycle) of PreS1-AuNP and fitting as heterogeneous ligand  
(coloured lines are experimental sensorgrams corresponding to different nanoparticle concentrations, namely red: 
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0.005 nM, blue: 0.010 nM, magenta: 0.020 nM, black: 0.038 mM, orange: 0.078 nm, dark red and dark blue: 0 .157 
mM; gray dashed lines are the best fitting in both graphs). 
 
 
A more realistic evaluation of ability of the PreS1-AuNp to selectively bind cancer cells was 
performed by using human HepG2 cells stably transfected with SB3 (HepG2/SB3 cells). Western 
blot experiments (see Supporting Information) indicate that, indeed, only HepG2/SB3 cells show a 
remarkable amount of SB3. These cells were incubated  with increasing concentrations of PreS1-
AuNPs using HepG2 and  1-AuNPs as control cells and nanoparticles, respectively. The results 
(Figure 3) revealed a remarkably higher binding of PreS1-AuNP nanoparticles in the HepG2/SB3 
cells compared to the controls. In particular, HepG2 cells did not bind either PreS1-AuNPs and 1-
AuNPs nanoparticles confirming the stealth features of the phosphorylcholine coating in the 
absence of the SB3 protein on the cells. On the other hand, SB3-transfected cells bound both 
nanoparticles, although at a different extent. In fact, the amount of PreS1-AuNPs bound to 
HepG2/SB3 cells was substantially higher than that of 1-AuNPs at any dose and in particular at the 
lower (0.5 µg/mL) concentration used. On one side, these data indicated an increased uptake of 
the nanoparticles conjugated with the targeting peptide mediated by its interaction with the SB3 
protein, on the other they also confirmed the affinity of the phosphorylcholine coating for SB3 
revealed by the SPR experiments. The better affinity of the PreS1-AuNPs for HepG2/SB3 cells 
compared to 1-AuNPs in these experiments indicated a lower unspecific interaction of the 
zwitterionic component of the monolayer or, more likely, a more appropriate presentation of SB3 
on the cells surface than on the chips used for the SPR experiments. It is not infrequent the 
immobilization of a protein on the surface for an SPR experiment alters its interaction with the 
target.  
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Figure 3 Binding specificity analysis of nanoparticles to HepG2/SB3 cells and controls (HepG2/control). Conditions: 1 
hour incubation at 37 °C and 5% CO2. Bars represent mean values ± SD of two different sets of experiments (two runs 
each). The gold cellular content was determined by atomic absorption analysis of cellular pellets. The X axis shows the 
different concentration of AuNPs utilized.  
 
The dose-response trend was quite flat, suggesting a threshold uptake of the nanoparticles 
is already reached at low concentrations. Consequently, we selected 1 µg/mL as the best 
experimental concentration at 1 hour incubation to assess the fate of the nanoparticles and, in 
particular their internalization into the cells. As reported in Figure 4, binding of PreS1-AuNP was 
more than 6 times higher than that of the nanoparticles without the peptide (1-AuNp). Trypsin 
treatment of HepG2/SB3 cells, which, as we have as previously reported allows to differentiate, at 
least in part, between HBV binding and internalization,
21
 did not cause any decrease of the 
amount of gold bound to the cells. This suggests that the nanoparticles were internalized and not 
just bound to the cell surface. This adds another possibility to explain the difference observed in 
the SPR and in vitro experiments. In fact it could be that binding is not much enhanced by SB3 
presence on the surface of the cells but whenever it occurs it induces efficient internalization of 
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the nanoparticles in them. We cannot exclude that this is due, at least in part, to an overall 
difference in endocytosis activity induced by SerpinB3. In any case the presence of the PreS1 
peptide is a requisite for the process to occur.  
 
 
Figure 4. Nanoparticles uptake by HepG2/SB3 cells. Conditions: 1 hour incubation at 1 µg/mL concentration with or 
without 5 minutes treatment with trypsin at 37°C. Negative controls were treated with PBS. The gold cellular content 
was determined by atomic absorption analysis of cellular pellets. Bars represent mean values ± SD of three different 
experiments. 
 
Cellular toxicity of the AuNPs was investigated by monitoring the cell growth curves upon 
incubation with and without the nanoparticles. All the curves were identical over the time interval 
investigated (96 h) indicating no cytotoxicity induced by the nanoparticles (Figure 5).  
 
Figure 5. Left panel: time course of the cell growth in the medium (blue trace), in the presence of 1µg/mL of 1-AuNP 
(red) or PreS1-AuNP (green); the cell index is a relative measure of cell number present in a well. Results are 
expressed as mean of automatically calculated cell indexes of three different experiments. Right panel: cell viability of 
the same solutions after 24 h. 
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CONCLUSION 
In conclusion, we reported here the facile preparation of stable, water soluble 2-nm gold 
nanoparticles that can be easily conjugated with a peptide bearing a thiol group.
33,34,35
 With 
respect to other conjugation methods, the use of the maleimide-thiol reaction in methanol allows 
the targeting molecule to be fully exposed on the surface of the nanoparticle thus ensuring a 
better presentation to the target. The data we have obtained put in evidence that the PreS1(21-
47) peptide is a suitable targeting agent for cells overexpressing the SB3 protein. Even more 
important is the evidence that the gold nanoparticles are internalized by the cells. The mechanism 
of internalization of the virus is far from being understood.
36,37
 It appears that the PreS1-SB3 
interaction is not the only factor. For instance, Hao et al.
38
 have suggested that ferritin light chain 
(FTL) is involved in the formation of a putative preS-FTL-SB3 triple complex. The SPR results, if we 
accept the hypothesis of a wrong orientation of SB3 on the chip surface, indicate a precise 
presentation of the protein to the virus surface is required for recognition. Harrison et al.
22
 have 
shown that the binding event does not involve the reactive site loop of SB3. This could imply the 
binding occurs at the surface of the protein supporting the suggestion that a wrong orientation is 
the cause of the unselective binding in the SPR experiments. Regardless the precise mechanism of 
binding and internalization our results are important in view of a possible use of these 
nanoparticles as carriers to deliver and internalize a suitable payload  in hepatocellular carcinoma 
treatment. Nanoparticle delivery to malignant tissues and cells is an hot topic Efficiency in the 
process, particularly as tumors are concerned, has been shown recently to be still very 
challenging.
39
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EXPERIMENTAL PROCEDURES 
Syntheses. Thiols 1 and 2 were prepared following previously published procedures.
30,40
 
Peptide PreS1(21-47) was purchased from JTP, Germany. Its purity was checked by HPLC and 
found to be better than 99%.  Conjugation to the nanoparticles and functionalization of the 
peptide were performed following standard protocols. Details are reported in the Supporting 
Information. 
Nanoparticles characterization. Nanoparticles 
1
H-NMR spectra were recorded using a 
Bruker AV300 spectrometer operating at 300 MHz. About 10 mg of nanoparticle were dissolved in 
0.6 ml of CD3OD and the spectrum was recorded. TEM images were recorded on a Jeol 300 PX 
electron microscope. One drop of sample solution was placed on the sample grid and the solvent 
was allowed to evaporate. UV-Visible spectra and kinetic traces were recorded on a Cary 50 
spectrophotometer equipped with thermostatted multiple cell holders. IR spectra were recorded 
on a Nicolet 5700 FT-IR spectrophotometer and reported in cm
-1
. AuNPs were dissolved in 
methanol at the concentration of 10 mg/mL then 20 µL of the solution casted onto a NaCl plate by 
an Eppendorf micropipette and dried using a hotplate. NMR spectra and TEM images are in Fig. 1 
and in the Supporting Information. 
Surface Plasmon Resonance analysis. SPR analyses were performed using a double 
channel Biacore X100 instrument (GE Healthcare, Uppsala, Sweden). Recombinant SB3 was 
produced after cloning human SB3 cDNA  in the directional expression vector pET101 (Invitrogen 
Carlsbad, CA), as previously described.
41
 A dextrane-coated gold chip (CM5) was activated by 
flowing a 1:1 mixture of 0.2 M N-ethyl-N-(3-dimethylaminopropyl) carbodiimide and 0.05 M N-
hydroxysuccinimide in water. A continuous flow of HEPES pH 7.4 was maintained. SB3 (50 μg/mL) 
in 10 mM sodium acetate (pH 5) was immobilized on the activated chip surface at a flow rate of 10 
μL/min to obtain an immobilization level of “Response Bound” of 1661 RU and “Response Final” of 
1840 RU. Excess of activated carboxylic groups on the chip was blocked with ethanolamine. 
Control channel was treated following the same protocol without protein immobilization.  Kinetic 
assays were performed with both PreS1AuNPs and 1-AuNP as control, following the instrument 
built-in standard protocol using HBS-EP+ buffer at pH 7.4 (0.1 M HEPES, 1.5 M NaCl. 30 mM EDTA, 
0.5% v/v P20 surfactant) by subsequent 180 sec injections of nanoparticle solutions at increasing 
concentration (0.005-0.157 nM) using NaCl 3 M as regeneration solution. Details are reported in 
the supporting information. 
Cellular uptake and viability analysis. To analyze the ability of nanoparticles to selectively 
bind SB3 in cells manipulated to over-express this serpin, in vitro experiments were carried out. 
HepG2 cells, derived from a human hepatoma (LGC Standards S.r.l., Sesto San Giovanni, MI, Italy) 
were stably transfected with a plasmid vector carrying the wild-type SB3 human gene 
(HepG2/SB3) or with the plasmid vector alone (HepG2/empty vector)  (pcDNA3.1D/V5-His-TOPO, 
Invitrogen Life Technologies, NY, USA) as previously reported.
42
 In preliminary experiments both 
cell lines were tested for SerpinB3 protein content by Western blot and only HepG2/SB3 showed a 
remarkable amount of this serpin (Supporting Information Figure S19). Both cell lines were initially 
incubated for 1 hour with increasing amounts (0.5, 1, 10 µg/ml) of PreS1-AuNPs or 1-AuNPs, as 
negative control, to define the best experimental conditions and to test the specificity of 
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functionalized nanoparticles binding to SB3 target protein. In order to evaluate if PreS1-AuNPs 
were internalized into SB3-expressing cells, trypsin treatment was carried out for 5’ at 37°C after 1 
hour incubation. Negative controls were treated with PBS for the same time frame. Real-time 
monitoring of the potential cytotoxicity of nanoparticles was carried out using the xCELLigence DP 
instrument (Roche Diagnostics, Mannheim, Germany) as described in the supplier’s instruction 
manual. HepG2/SERPINB3 cells were seeded (50,000 cells/well) in the E-Plate 96, maintained at 
37°C in 5% CO2 atmosphere and treated with 1 µg/mL of PreS1AuNPs or of 1-AuNPs or with 
medium. Cell cultures not treated with nanoparticles were used as control. The cell Index values (a 
quantitative measure of the cell number present in a well) were achieved using the RTC software 
(version 1.2, Roche Diagnostics) and monitored every 10 minutes for 96 hours. 
Atomic absorption analysis. In order to analyze the amount of nanoparticles entered into 
the cells,  atomic absorption analysis was carried out. The digestion of cellular pellets was 
accomplished by addition of 0.5 ml of aqua regia (HCl 36% : HNO3 3%=3:1) to each cell sample 
followed by heating at 70°C for 1 h in a sealed vial. Subsequently, an aliquot of 250 µl of digestion 
solution was transferred into a 15 ml polypropylene tube and filled to a total volume of 10 ml with 
a 3% solution of HNO3. Gold content was determined by standard Atomic Absorption 
measurements. 
Western blot analysis. Fifty µg of total protein content from each cellular extract, obtained 
by cellular protein extraction using RIPA lysis buffer, were loaded on 10% polyacrylamide gel. 
Antigenic detection was carried out by enhanced chemiluminescence (Amersham, Arlington 
Height, IL) and densitometric analysis was assessed using VersaDoc Imaging system (Bio-Rad 
Laboratories, Hercules, CA). The following antibodies were used: monoclonal anti-SERPINB3 
antibody (0.5 µg/ml , R&D SYSTEMS  Minneapolis, MN), monoclonal anti-β-actin antibody (1:1000,  
Sigma-Aldrich, St. Luis, MO) and anti-mouse horseradish peroxidase conjugated secondary 
antibody (1:1000, Amersham Bioscience, Arlington Height, IL). 
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